Endoscopic sleeve gastroplasty (ESG) for morbid obesity: how effective is it?
Gontrand Lopez-NavaJanese LasterAnuradha NegiStephanie Fook-ChongI Bautista-CastañoRavishankar AsokkumarPublished in: Surgical endoscopy (2021)
ESG induced significant weight loss in all classes of obesity. In class III obesity, the weight loss achieved was significantly higher at 1 year. In patients declining or unsuitable for surgery, ESG could be considered as an alternative treatment option.
Keyphrases
- weight loss
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- insulin resistance
- end stage renal disease
- metabolic syndrome
- weight gain
- obese patients
- type diabetes
- chronic kidney disease
- newly diagnosed
- glycemic control
- ejection fraction
- minimally invasive
- peritoneal dialysis
- coronary artery bypass
- skeletal muscle
- drug induced
- oxidative stress
- diabetic rats
- acute coronary syndrome
- coronary artery disease
- adipose tissue
- patient reported outcomes
- stress induced